A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma

Clinical Cancer Research

Volumn 20, Issue 23, 2014, Pages 5976-5985

  Lim, Ho Yeong ^a   Heo, Jeong ^b   Choi, Hye Jin ^c   Lin, Cheng Yao ^d   Yoon, Jung Hwan ^e   Hsu, Chiun ^f   Rau, Kun Ming ^g,h   Poon, Ronnie T P ⁱ   Yeo, Winnie ^j   Park, Joong Won ^k   Tay, Miah Hiang ^l   Hsieh, Wen Son ^m   Kappeler, Christian ⁿ   Rajagopalan, Prabhu ^o   Krissel, Heiko ⁿ   Jeffers, Michael ^o   Yen, Chia Jui ^p   Tak, Won Young ^q  

^a Samsung Medical Center   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d CHI MEI MEDICAL CENTER   (Taiwan)

^e Seoul National University   (South Korea)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^h CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

ⁱ UNIVERSITY OF HONG KONG   (Hong Kong)

^j CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^k National Cancer Center   (South Korea)

^l Oncocare Cancer Centre   (Singapore)

^m NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

ⁿ BAYER PHARMA AG   (Germany)

^o BAYER CORPORATION   (United States)

^p NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^q Kyungpook National University School of Medicine   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

REFAMETINIB; SORAFENIB; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARBANILAMIDE DERIVATIVE; DIPHENYLAMINE; N-(3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)-6-METHOXYPHENYL)-1-(2,3-DIHYDROXYPROPYL)CYCLOPROPANE-1-SULFONAMIDE; NICOTINAMIDE; SULFONAMIDE;

ACNE; ACUTE CORONARY SYNDROME; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLURRED VISION; BRAIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CATARACT; DIARRHEA; DIZZINESS; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; EVENING DOSAGE; FEMALE; FEVER; GENE MUTATION; HEADACHE; HEART VENTRICLE TACHYCARDIA; HEPATITIS B; HONG KONG; HUMAN; HYPERTENSION; ILEUS; INOPERABLE CANCER; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE DRUG DOSE; NAUSEA; ONCOGENE RAS; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; RASH; RETINA DISEASE; RETINOPATHY; SEIZURE; SEPSIS; SIDE EFFECT; SINGAPORE; SINGLE DRUG DOSE; SOUTH KOREA; TAIWAN; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR LYSIS SYNDROME; UPPER GASTROINTESTINAL BLEEDING; VITREOUS FLOATERS; VOMITING; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; LIVER NEOPLASMS; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; DIPHENYLAMINE; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84918777261     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-3445     Document Type: Article

References (21)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76.
3. London WT, McGlynn KA. Liver cancer. In: Schottenfeld D, Fraumeni J.F.Jr, editors. Clear epidemiology and prevention. New York: Oxford University Press; 2006. p. 763-86.
4. Hung H. Treatment modalities for hepatocellular carcinoma. Curr Cancer Drug Targets 2005;5:131-8.
5. Poon RTP, Fan ST, Tsang FHF, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 2002;235:466-86.
6. Harrison LE, Koneru B, Baramipour P, Fisher A, Barone A, Wilson D, et al. Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg 2003;197:759-64.
7. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers (Version 2.2014). Available from: http://www.nccn.org/professionals/physician-gls/pdf/hepatobiliary.pdf.
8. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
9. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
10. Iverson C, Larson G, Lai C, Yeh LT, Dadson C, Weingarten P, et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res 2009;69:6839-47.
11. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-310.
12. Huynh H, Nguyen TTT, Pierce Chow KH, Tan PH, Soo KC, Tran E. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 2003;3:19.
13. Schmieder R, Puehler F, Neuhaus R, Kissel M, Adjei AA, Miner JN, et al. Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma. Neoplasia 2013;15:1161-71.
14. Weekes CD, Von Hoff DD, Adjei AA, Leffingwell DP, Eckhardt SG, Gore L, et al. Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res 2013;19:1232-43.
15. Breunig C, Mueller BJ, Umansky L, Wahl K, Hoffmann K, Lehner F, et al. BRaf and MEK inhibitors differentially regulate cell fate and microenvironment in human hepatocellular carcinoma. Clin Cancer Res 2014;20:2410-23.
16. Marrero JA, Lencioni R, Ye SY, Kudo M, Bronowicki JP, Chen XP, et al. Final analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma [HCC] and Of its treatment with sorafeNib [Sor]) in >3000 Sor-treated patients (pts): clinical findings in pts with liver dysfunction [abstract 4126]. J Clin Oncol (Meeting Abstracts) 2013;31.
17. Baselga J, Segalla JG, Roche H, Del Giglio A, Pinczowski H, Ciruelos EM, et al. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 2012;30:1484-91.
18. Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Sakata K, Matsugaki S, et al. Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma. Oncology 2013;84:108-14.
19. Minami H, Kawada K, Ebi H, Kitagawa K, Kim YI, Araki K, et al. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 2008;99:1492-8.
20. Wellcome Trust Sanger Institute. Catalogue of somatic mutations in cancer (COSMIC). Available from: http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/. Accessed October 22, 2014.
21. Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res 2012;18:3462-9.